Bionime Corp (4737) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bionime Corp (4737) has a cash flow conversion efficiency ratio of 0.038x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$66.44 Million ≈ $2.09 Million USD) by net assets (NT$1.76 Billion ≈ $55.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 4737 equity financing ratio to measure how much of total assets are equity-financed.
Bionime Corp - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Bionime Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Bionime Corp cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Bionime Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bionime Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LAUNCH TECH CO. H YC-01
F:LAN
|
N/A |
|
Silver X Mining Corp
V:AGX
|
0.051x |
|
Baiksan
KO:035150
|
0.077x |
|
Caribou Biosciences Inc
NASDAQ:CRBU
|
-0.170x |
|
Cape Industries Ltd
KQ:064820
|
-1.206x |
|
Owlet Inc
NYSE:OWLT
|
-0.139x |
|
Ajiya Bhd
KLSE:7609
|
-0.020x |
|
Yg Plus Inc
KO:037270
|
0.143x |
Annual Cash Flow Conversion Efficiency for Bionime Corp (2009–2025)
The table below shows the annual cash flow conversion efficiency of Bionime Corp from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see 4737 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.76 Billion ≈ $55.31 Million |
NT$494.80 Million ≈ $15.59 Million |
0.282x | +2626.07% |
| 2024-12-31 | NT$1.89 Billion ≈ $59.51 Million |
NT$19.53 Million ≈ $615.30K |
0.010x | -89.87% |
| 2023-12-31 | NT$1.99 Billion ≈ $62.80 Million |
NT$203.44 Million ≈ $6.41 Million |
0.102x | +49.24% |
| 2022-12-31 | NT$2.08 Billion ≈ $65.55 Million |
NT$142.29 Million ≈ $4.48 Million |
0.068x | -47.36% |
| 2021-12-31 | NT$2.08 Billion ≈ $65.41 Million |
NT$269.72 Million ≈ $8.50 Million |
0.130x | +23.66% |
| 2020-12-31 | NT$2.07 Billion ≈ $65.24 Million |
NT$217.56 Million ≈ $6.85 Million |
0.105x | -46.98% |
| 2019-12-31 | NT$2.05 Billion ≈ $64.49 Million |
NT$405.56 Million ≈ $12.78 Million |
0.198x | +223.97% |
| 2018-12-31 | NT$1.99 Billion ≈ $62.79 Million |
NT$121.90 Million ≈ $3.84 Million |
0.061x | +329.29% |
| 2017-12-31 | NT$2.08 Billion ≈ $65.46 Million |
NT$29.60 Million ≈ $932.53K |
0.014x | -91.95% |
| 2016-12-31 | NT$2.59 Billion ≈ $81.50 Million |
NT$457.84 Million ≈ $14.42 Million |
0.177x | +124.53% |
| 2015-12-31 | NT$2.54 Billion ≈ $80.08 Million |
NT$200.37 Million ≈ $6.31 Million |
0.079x | -70.49% |
| 2014-12-31 | NT$1.35 Billion ≈ $42.44 Million |
NT$359.84 Million ≈ $11.34 Million |
0.267x | +121.73% |
| 2013-12-31 | NT$1.07 Billion ≈ $33.73 Million |
NT$128.98 Million ≈ $4.06 Million |
0.120x | +411.49% |
| 2012-12-31 | NT$1.00 Billion ≈ $31.54 Million |
NT$23.57 Million ≈ $742.74K |
0.024x | -88.22% |
| 2011-12-31 | NT$1.09 Billion ≈ $34.19 Million |
NT$216.93 Million ≈ $6.83 Million |
0.200x | +1387.47% |
| 2010-12-31 | NT$1.02 Billion ≈ $32.02 Million |
NT$13.66 Million ≈ $430.40K |
0.013x | -95.85% |
| 2009-12-31 | NT$640.89 Million ≈ $20.19 Million |
NT$207.56 Million ≈ $6.54 Million |
0.324x | -- |
About Bionime Corp
Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Belarus, Algeria, the United Arab Emirates, Egypt, and internationally. The company manufactures and sells blood glucose meters and test strips to medical equipment companies, pharmacies, and hospitals, as well as offers blood glucose monitoring devices and systems under the RIGHTEST… Read more